Systematic Evaluation of Genetic Variants in Three Biological Pathways on Patient Survival in Low-Stage Non-small Cell Lung Cancer V. Shane Pankratz,

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

PUBLISH ONLY Journal of Thoracic Oncology

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Gender differences in non–small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002 Antonio L Visbal, MD, Brent.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Association of the CHRNA3 Locus with Lung Cancer Risk and Prognosis in Chinese Han Population Xiaomin Niu, MD, Zhiwei Chen, MD, PhD, Shengping Shen,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Electronic Updates for JTO Readers

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis Ping Zhan, MD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer:

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Liang Wang, MD, Jeremiah A. Aakre, BS, Ruoxiang Jiang, BS, Randolph S

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Ping Yang, MD, PhD, Kimary Kulig, PhD, MPH, Jennifer M

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers Dong Xie, MD, PhD, Randolph.

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Yang Zhang, MD, Haiquan Chen, MD, PhD

PUBLISH ONLY Journal of Thoracic Oncology

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North.

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell.

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

RTOG 0017: A Phase I Trial of Concurrent Gemcitabine/Carboplatin or Gemcitabine/Paclitaxel and Radiation Therapy (“Ping-Pong Trial”) Followed By Adjuvant.

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Ethnic Differences in the Management of Lung Cancer in New Zealand

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

International Thymic Malignancies Interest Group: A Way Forward

Genetic Polymorphisms in the Polycomb Group Gene EZH2 and the Risk of Lung Cancer Kyong-Ah Yoon, MD, Hye Jin Gil, MS, Jihye Han, MS, Jaehee Park, MS,

The future of cardiac surgery training: A survival guide

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Neal S Goldstein, MD The Annals of Thoracic Surgery

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Spontaneous Smoking Cessation Before Lung Cancer Diagnosis

Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-small Cell Lung Cancer Joon Suk Park, MD, Hee Chul Yang, MD, Hong Kwan Kim, MD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node- negative T3 and T4 non–small cell lung cancer Benedict D.T. Daly, MD,

Presentation transcript:

Systematic Evaluation of Genetic Variants in Three Biological Pathways on Patient Survival in Low-Stage Non-small Cell Lung Cancer V. Shane Pankratz, PhD, Zhifu Sun, MD, Jeremiah Aakre, BS, Yan Li, MD, PhD, Cassandra Johnson, DVM, Yolanda I. Garces, MD, Marie C. Aubry, MD, Julian R. Molina, MD, PhD, Dennis A. Wigle, MD, PhD, Ping Yang, MD, PhD Journal of Thoracic Oncology Volume 6, Issue 9, Pages 1488-1495 (September 2011) DOI: 10.1097/JTO.0b013e318223bf05 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Adjusted survival curves for the nine combinations of the top two single-nucleotide polymorphism (SNP) genotypes. Each line represents one of the nine genotype combinations between rs3768490 and rs1729786. Average method was used for the multivariate adjusted curves. The black line (CC/GG of rs3768490 and rs1729786) was the reference group used for statistical testing of significance. Survival probability from 0 to 0.5 on y axis was cut for better readability of the curves, and survival time was truncated at 5 years post diagnosis. Journal of Thoracic Oncology 2011 6, 1488-1495DOI: (10.1097/JTO.0b013e318223bf05) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Adjusted survival curves for genotype risk scores. Adjusted survival curves were created for the patients with genotype risk scores of 0/1, 2, 3, and 4 using the average method. The adjusted variables included age at diagnosis, lung cancer stage, surgery subtype, and adjuvant therapy. Patients with a score of 0 were not statistically different from those with a score of 1, and the 2 groups were therefore combined and used as reference (black line). Survival probability from 0 to 0.5 on the y axis was cut for better readability of the curves, and survival time was truncated at 5 years post diagnosis. Journal of Thoracic Oncology 2011 6, 1488-1495DOI: (10.1097/JTO.0b013e318223bf05) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions